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nosed or for ﬁrst relapse of AML or MDS. IFI subjects had been
diagnosed with proven or probable IFI according to EORTC
criteria and received antifungal therapy. Match criteria were
duration of febrile neutropenia, age and type of chemotherapy.
Resource utilization data included length of stay, mechanical
ventilation, parenteral nutrition, diagnostic procedures, antifun-
gal agents and cost-intensive concomitant medication. Direct
medical cost was calculated from the hospital provider perspec-
tive. RESULTS: A total of 108 patients were enrolled at 5
maximum care hospitals, 36 IFI patients and 72 controls. Mean
age was 61.5 years (IFI group) and 61.2 years (control group),
50% and 63% were male, respectively. Primary diagnosis was
AML in 97% of IFI patients and in 99% of control patients. The
vast majority of IFI patients (74%) had invasive aspergillosis. IFI
patients stayed on average 12 days longer in the hospital than
control patients. In the IFI group all patients (100%) and in the
control group 89% of patients received antifungal drugs. Mean
direct cost per patient amounted to €51,517 in the IFI group and
€30,454 in the control group. Incremental cost of €21,063 was
dominated by cost for antifungal drugs (36%), hospital stay
(32%) and blood products (23%). CONCLUSIONS: The eco-
nomic burden of IFI in patients with AML or MDS is remarkable
from the perspective of hospitals in Germany. Therefore, anti-
fungal prophylaxis in patients with AML or MDS should be
considered because of clinical and economic reasons.
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OBJECTIVES: Treatment regimens in extensively pre-treated
advanced and metastatic breast cancer (MBC) patients may
confer similar efﬁcacy but have different toxicity proﬁles. This
study aimed to identify toxicities associated with chemotherapy
regimens in late-line breast cancer and to estimate direct costs of
managing those toxicities. METHODS: A PubMed search iden-
tiﬁed global Phase II/III studies of single agent and combination
treatment regimens for advanced and MBC patients previously
treated with 2 chemotherapy regimens. The proportion of
patients experiencing grade 3 and 4 toxicities was abstracted.
Using expert opinion, reported toxicities were placed into repre-
sentative groupings based on similarities in event types and treat-
ment costs (e.g., extremity pain, pain, arthralgia, headache) and
a proxy for each grouping (e.g., pain) was identiﬁed for purposes
of estimating direct costs of treatment for grade 3 and grade 4
(inpatient) toxicities. Unit costs were estimated using data from
Health Care Utilization Project, Medicare reimbursement rates,
and Redbook and updated to 2008 USD using the medical care
component of the Consumer Price Index. RESULTS: This study
included toxicity information from seven treatment regimens
studied in the salvage setting. The most commonly reported
grade 3 toxicities were hematological (albumin-bound paclitaxel,
capecitabine, gemcitabine, ixabepilone + capecitabine), cardiac
(bevacizumab + capecitabine), fatigue (ixabepilone), and
gastrointestinal-related (sunitinib). The most commonly reported
grade 4 toxicities were hematological (albumin-bound paclitaxel,
capecitabine, ixabepilone, ixabepilone + capecitabine), embolic
(bevacizumab + capecitabine) and anemia-related (capecitabine,
gemcitabine). Estimated total direct costs of treating all toxicities
by treatment regimen were: sunitinib ($107), gemcitabine
($585), albumin-bound paclitaxel ($1446), bevacizumab +
capecitabine ($3493), capecitabine ($3775), ixabepilone
($4403), and ixabepilone + capecitabine ($16279). CONCLU-
SIONS: Treatment regimens in extensively pre-treated breast
cancer patients may have similar efﬁcacy but vary greatly in the
cost of managing treatment-related toxicities: $107 to $16279 in
this study. The costs of these toxicities should be included in
future economic evaluations comparing the clinical and cost-
effectiveness of alternative treatment regimens for advanced and
MBC.
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OBJECTIVES: To estimate the costs of infusional 5-ﬂuorouracil
(5-FU) and oral capecitabine (CAP) in Metastatic Colorectal
Cancer (MCC) patients. METHODS: Observational, retrospec-
tive study estimating direct medical costs (medications, adminis-
tration patterns, infusion device insertion, tests, visits, adverse
event management) after treatment with ﬁrst-line 5-FU or CAP,
with or w/o association of other chemotherapies. Data were
collected from patients’ charts in 5 Oncology ambulatories.
Average per patient direct cost was estimated by national tariffs
and market retail prices (2007 values) in the Italian Healthcare
Service (IHCS) perspective. RESULTS: Data were collected on
202 subjects (136 on 5-FU; 66 on CAP). A total of 93% 5-FU-
patients and 47% CAP-patients received infusional chemo-
therapy agents in association. Alternatives differed in the mean
number of cycles planned (5-FU 10.7 vs CAP 6.7) and adminis-
tered (5-FU 9.7 vs CAP 6.4). In the IHCS perspective, average
total cost was €12,029 (SD €5,521) per 5-FU-patient vs. €5,781
(SD €4,933) per CAP-patient; considering only patients in com-
bination regimens mean total cost per patient were €12,534 in
5-FU plus oxaliplatin or irinotecan and €9,986 in CAP plus
oxaliplatin or irinotecan. Administration of infusional therapy in
Day Hospital (DH) accounted for 51% and 28% of total costs in
5-FU and CAP group, respectively; drug cost amounted to 37%
in 5-FU and 60% CAP arm. Arms differed as to catheter inser-
tion, adverse event management and chemo-supportive therapy
costs. Oral route remained the most economic alternative over
the infusional route in all sensitivity analyses. CONCLUSIONS:
Management of MCC patients by oral chemotherapies may be
economically rational to IHCS.
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OBJECTIVES: To quantify the ﬁnancial impact of home care
support teams versus inpatient palliative care in a university
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